Mediators and Cytokines in Persistent Allergic Rhinitis and Nonallergic Rhinitis with Eosinophilia SyndromeGröger M.a · Klemens C.a · Wendt S.a · Becker S.a · Canis M.b · Havel M.a · Pfrogner E.a · Rasp G.c · Kramer M.F.a
Departments of Oto-Rhino-Laryngology, Head and Neck Surgery,aLudwig Maximilians University Munich, Munich, and bGeorg August University, Göttingen, Germany; cDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Paracelsus University of Salzburg, Salzburg, Austria
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Patients with nonallergic rhinitis with eosinophilia syndrome (NARES) show typical symptoms of persistent allergic rhinitis (PAR). The aim of the present study was to compare nasal cytokine patterns between NARES and PAR. Methods: Nasal secretions of 31 patients suffering from NARES, 20 patients with PAR to house dust mite and 21 healthy controls were collected using the cotton wool method and analyzed for interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1β (MIP-1β) by Bio-Plex Cytokine Assay as well as eosinophil cationic protein (ECP) and tryptase by UniCAP-FEIA. Results: NARES and PAR presented elevated levels of tryptase, while ECP was markedly increased solely in NARES compared to both the controls and PAR. Elevated levels of IL-1β, IL-17, IFN-γ, TNF-α and MCP-1 were found in NARES compared to the controls as well as PAR. MIP-1β was elevated in NARES and PAR, while IL-4, IL-6 and G-CSF showed increased levels in NARES, and IL- 5 was elevated in PAR only. Conclusions: In patients with NARES and PAR, eosinophils and mast cells appear to be the pivotal cells of inflammation, reflected by high levels of tryptase and ECP as well as IL-5 and GM-CSF as factors for eosinophil migration and survival. The elevated levels of proinflammatory cytokines in NARES may indicate the chronic, self-perpetuating process of inflammation in NARES which seems to be more pronounced than in PAR. IL-17 might be a factor for neutrophilic infiltration or be responsible for remodeling processes in NARES.
© 2012 S. Karger AG, Basel
- van Rijswijk JB, Blom HM, Fokkens WJ: Idiopathic rhinitis, the ongoing quest. Allergy 2005;60:1471–1481.
- Bousquet J, van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147–S334.
- Nathan RA, Meltzer EO, Derebery J, Campbell UB, Stang PE, Corrao MA, Allen G, Stanford R: The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008;29:600–608.
- Naclerio RM, Baroody F: Understanding the inflammatory processes in upper allergic airway disease and asthma. J Allergy Clin Immunol 1998;101:S345–S351.
- Frieri M: Inflammatory issues in allergic rhinitis and asthma. Allergy Asthma Proc 2005;26:163–169.
- Crobach M, Hermans J, Kaptein A, Ridderikhoff J, Mulder J: Nasal smear eosinophilia for the diagnosis of allergic rhinitis and eosinophilic non-allergic rhinitis. Scand J Prim Health Care 1996;14:116–121.
- Moneret-Vautrin DA, Jankowski R, Bene MC, Kanny G, Hsieh V, Faure G, Wayoff M: NARES: a model of inflammation caused by activated eosinophils? Rhinology 1992;30:161–168.
- Powe DG, Groot KT, Sisson M, Blokhuis BJ, Kramer MF, Jones NS, Redegeld FA: Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. J Allergy Clin Immunol 2010;125:139–145.
- Powe DG, Huskisson RS, Carney AS, Jenkins D, Jones NS: Evidence for an inflammatory pathophysiology in idiopathic rhinitis. Clin Exp Allergy 2001;31:864–872.
- Vignali DA: Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243–255.
- Klimek L, Rasp G: Norm values for eosinophil cationic protein in nasal secretions: influence of specimen collection. Clin Exp Allergy 1999;29:367–374.
- Riechelmann H, Deutschle T, Friemel E, Gross HJ, Bachem M: Biological markers in nasal secretions. Eur Respir J 2003;21:600–605.
- Canakcioglu S, Tahamiler R, Saritzali G, Alimoglu Y, Isildak H, Guvenc MG, Acar GO, Inci E: Evaluation of nasal cytology in subjects with chronic rhinitis: a 7-year study. Am J Otolaryngol 2009;30:312–317.
- Klemens C, Rasp G, Jund F, Hilgert E, Devens C, Pfrogner E, Kramer MF: Mediators and cytokines in allergic and viral-triggered rhinitis. Allergy Asthma Proc 2007;28:434–441.
- Kramer MF, Burow G, Pfrogner E, Rasp G: In vitro diagnosis of chronic nasal inflammation. Clin Exp Allergy 2004;34:1086–1092.
- Segundo GR, Gomes FA, Fernandes KP, Alves R, Silva DA, Taketomi EA: Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments. Biologics 2009;3:469–474.
- Woschnagg C, Rubin J, Venge P: Eosinophil cationic protein (ECP) is processed during secretion. J Immunol 2009;183:3949–3954.
- Rondon C, Fernandez J, Lopez S, Campo P, Dona I, Torres MJ, Mayorga C, Blanca M: Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. J Allergy Clin Immunol 2009;124:1005–1011.
- Wagenmann M, Schumacher L, Bachert C: The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005;60:1132–1138.
- Bachert C, Hauser U, Prem B, Rudack C, Ganzer U: Proinflammatory cytokines in allergic rhinitis. Eur Arch Otorhinolaryngol 1995;252(suppl 1):S44–S49.
- Bachert C, van Kempen M, van Cauwenberge P: Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999;118:375–379.
- Milanese M, Ricca V, Canonica GW, Ciprandi G: Eosinophils, specific hyperreactivity and occurrence of late phase reaction in allergic rhinitis. Eur Ann Allergy Clin Immunol 2005;37:7–10.
- Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Bagnasco M, Canonica GW: Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects: relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994;150:1653–1659.
- Canonica GW, Compalati E: Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol 2009;158:260–271.
- Storms WW: Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. Ann Allergy Asthma Immunol 2003;91:131–140.
- Louten J, Boniface K, de Waal MR: Development and function of Th17 cells in health and disease. J Allergy Clin Immunol 2009;123:1004–1011.
- Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430–438.
- Oboki K, Ohno T, Saito H, Nakae S: Th17 and allergy. Allergol Int 2008;57:121–134.
Hellgren J, Toren K: Nonallergic occupational rhinitis. Clin Allergy Immunol 2007;19:241–248.
Shusterman D: Environmental nonallergic rhinitis. Clin Allergy Immunol 2007;19:249–266.
- McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, Kolls JK: Th17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008;181:4089–4097.
- Wang X, Dong Z, Zhu DD, Guan B: Expression profile of immune-associated genes in nasal polyps. Ann Otol Rhinol Laryngol 2006;115:450–456.
- Molet SM, Hamid QA, Hamilos DL: IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate. Laryngoscope 2003;113:1803–1812.
- Saitoh T, Kusunoki T, Yao T, Kawano K, Kojima Y, Miyahara K, Onoda J, Yokoi H, Ikeda K: Role of interleukin-17A in the eosinophil accumulation and mucosal remodeling in chronic rhinosinusitis with nasal polyps associated with asthma. Int Arch Allergy Immunol 2010;151:8–16.
- Moneret-Vautrin DA, Hsieh V, Wayoff M, Guyot JL, Mouton C, Maria Y: Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. Ann Allergy 1990;64:513–518.
- Hershey GK: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003;111:677–690.
- Scavuzzo MC, Rocchi V, Fattori B, Ambrogi F, Carpi A, Ruffoli R, Manganelli S, Iannessi F: Cytokine secretion in nasal mucus of normal subjects and patients with allergic rhinitis. Biomed Pharmacother 2003;57:366–371.
- Ciprandi G, Vizzaccaro A, Cirillo I, Tosca M, Massolo A, Passalacqua G: Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int Arch Allergy Immunol 2005;136:266–272.
- Bachert C, Wagenmann M, Hauser U, Rudack C: IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837–842.
- Egan RW, Umland SP, Cuss FM, Chapman RW: Biology of interleukin-5 and its relevance to allergic disease. Allergy 1996;51:71–81.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.